INGN vs MLYS
INGN: Inogen is a medical technology company developing portable oxygen concentrators and respiratory devices to improve mobility and quality of life for patients with chronic lung diseases like COPD. MLYS: Mineralys is a clinical-stage biopharmaceutical company pursuing FDA approval of lorundrostat, a selective aldosterone synthase inhibitor targeting resistant hypertension and related cardiorenal diseases.
Side-by-side fundamentals
| Metric | INGN | MLYS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.51 | $27.01 | |
| Market cap as of 2026-07-23 | $174M | $2.4B | |
| Net margin as of 2026-07-23 | -7.1% | n/a | |
| Gross margin as of 2026-07-23 | +44.3% | n/a | |
| Operating margin as of 2026-07-23 | -9.1% | n/a | |
| ROE as of 2026-07-23 | -12.9% | -27.9% | INGN higher |
| ROA as of 2026-07-23 | -8.3% | -27.0% | INGN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +3.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -2.6% | n/a | |
| Beta as of 2026-07-23 | 1.61 | 0.59 | |
| 1-year return as of 2026-07-22 close | +2.7% | +102.1% | MLYS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.